5 news items
Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024
CRNX
3 Jun 24
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX
3 Jun 24
Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
CRNX
3 Jun 24
):In this initial analysis of this Phase 2 trial (TouCAHn), people with classic CAH were treated with once-daily, oral atumelnant and assessed for safety
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
CRNX
30 May 24
the therapeutic potential and clinical benefits or safety profile thereof. These forward-looking statements speak only as of the date of this press
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
CRNX
8 May 24
will be Presented, in Addition to New Long-Term Safety and Efficacy FindingsSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE
- Prev
- 1
- Next